Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Overview
- PESTEL Analysis
- Political
- Economic
- Social
- Technological
- Environmental
- Legal
- Porter’s Five Forces Analysis
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Potential of New Entrants
- Threat of Substitutes
- Competition in the Industry
- Supply Chain and Logistics for Hematological Instruments
Chapter 3 Market Dynamics
- Market Drivers
- Incidence of Blood Disorders
- Rising Use of Automation
- Diagnosis of Hematology Disorders
- Increasing Government and Private Funding for Treatment
- Market Restraints
- High Cost of Instruments
- High Cost of Treatment
- Reimbursement Challenges for Physicians
- Market Opportunities
- Rising Health Awareness
- Emerging Economies
Chapter 4 Patent Landscape and Current Developments in Drugs
- Patent Landscape
- New Approvals
Chapter 5 Emerging Technologies and Developments
- Overview
- Emerging Technologies
- AI-Assisted Diagnosis
- Next-Generation Sequencing (NGS)
- Microfluidics and Lab-on-a-Chip Devices
- Gene Therapies
- Immunotherapies
- Clinical Trials
Chapter 6 Market Segmentation Analysis
- Segmentation Breakdown
- Segmentation by Market
- Hematological Disorders Diagnostics Market
- Hematological Disorders Diagnostic Market, By Product Type
- Hematological Disorders Diagnostic Market, By End User
- Hematology Drug Market
- Hematology Drug Market, By Drug Type
- Geographic Breakdown
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 7 Competitive Intelligence
- Leading Companies
- Hematological Disorder Diagnostics
- Hematological Disorder Drugs
- New Developers of Drugs for Rare Hematology Disorders
List of Tables
Summary Table: Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, Through 2029
Table 1: Blood-Related Disorders
Table 2: Incidence of Blood Cancer Types in U.S., 2023
Table 3: Total Cost of Care for CLL Patients Treated in the U.S., 2023
Table 4: Hematology Drugs and their Patent Expiration Dates, 2024
Table 5: Approved Hematology Drugs, 2023
Table 6: Clinical Trial Studies on Leukemia, March 2024
Table 7: Clinical Trial Studies on Lymphoma, March 2024
Table 8: Clinical Trial Studies on Bleeding Disorders, March 2024
Table 9: Clinical Trial Studies on Myelofibrosis, March 2024
Table 10: Clinical Trial Studies on Anemia, March 2024
Table 11: Clinical Trial Studies on Multiple Myeloma, March 2024
Table 12: Clinical Trial Studies on Thalassemia, March 2024
Table 13: Global Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 14: Global Market for Diagnostics for Hematological Disorders, by Region, Through 2029
Table 15: Global Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 16: Global Market for Hematology Instruments and Software, by Region, Through 2029
Table 17: Global Market for Hematology Reagents, by Region, Through 2029
Table 18: Global Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 19: Global Market for Hematology Diagnosis in Diagnostic Centers, by Region, Through 2029
Table 20: Global Market for Hematology Diagnosis in Hospitals and Clinics, by Region, Through 2029
Table 21: Global Market for Hematology Diagnosis in Other End Users, by Region, Through 2029
Table 22: Global Market for Hematology Drugs, by Region, Through 2029
Table 23: Global Market for Hematology Drugs, by Drug Type, Through 2029
Table 24: Drugs Approved for Hematologic Cancers
Table 25: Global Market for Hematology Oncology Drugs, by Region, Through 2029
Table 26: Global Market for Hematology Non-Oncology Drugs, by Region, Through 2029
Table 27: Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, Through 2029
Table 28: North American Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
Table 29: North American Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 30: North American Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 31: North American Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 32: North American Market for Hematology Drugs, by Drug Type, Through 2029
Table 33: European Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
Table 34: European Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 35: European Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 36: European Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 37: European Market for Hematology Drugs, by Drug Type, Through 2029
Table 38: Incidence of Blood-Related Cancers, by Country, 2022
Table 39: Asia-Pacific Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
Table 40: Asia-Pacific Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 41: Asia-Pacific Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 42: Asia-Pacific Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 43: Asia-Pacific Market for Hematology Drugs, by Drug Type, Through 2029
Table 44: Asia-Pacific Incidence of Blood-Related Cancers, by Country, 2022
Table 45: RoW Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 46: RoW Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 47: RoW Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 48: RoW Market for Hematology Drugs, by Drug Type, Through 2029
Table 49: Revenue Generated by Drugs for Hematology Disorders, 2023
Table 50: New Developers of Drugs for Hematology Disorders
Table 51: Report Sources
Table 52: Abbreviations Used in This Report
Table 53: Abbott: Company Snapshot
Table 54: Abbott: Financial Performance, F.Y. 2022 and 2023
Table 55: Abbott: Product Portfolio
Table 56: Abbott: News/Key Developments, 2023
Table 57: Amgen Inc.: Company Snapshot
Table 58: Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 59: Amgen Inc.: Product Portfolio
Table 60: Amgen Inc.: News/Key Developments, 2021-2024
Table 61: Bio-Rad Laboratories Inc.: Company Snapshot
Table 62: Bio-Rad Laboratories Inc.: Financial Performance, FY 2022 and 2023
Table 63: Bio-Rad Laboratories Inc.: Product Portfolio
Table 64: Bio-Rad Laboratories Inc.: News/Key Developments, 2023
Table 65: Bristol Myers Squibb Co.: Company Snapshot
Table 66: Bristol Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 67: Bristol Myers Squibb Co.: Product Portfolio
Table 68: Bristol Myers Squibb Co.: News/Key Developments, 2023 and 2024
Table 69: Danaher Corp.: Company Snapshot
Table 70: Danaher Corp.: Financial Performance, FY 2022 and 2023
Table 71: Danaher Corp.: Product Portfolio
Table 72: Danaher Corp.: News/Key Developments, 2022-2024
Table 73: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 74: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 75: F. Hoffmann-La Roche Ltd: Product Portfolio
Table 76: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
Table 77: Novartis AG: Company Snapshot
Table 78: Novartis AG: Financial Performance, FY 2022 and 2023
Table 79: Novartis AG: Product Portfolio
Table 80: Novartis AG: News/Key Developments, 2022
Table 81: Sanofi: Company Snapshot
Table 82: Sanofi: Financial Performance, FY 2022 and 2023
Table 83: Sanofi: Product Portfolio
Table 84: Sanofi: News/Key Developments, 2023
Table 85: Sysmex Corp.: Company Snapshot
Table 86: Sysmex Corp.: Financial Performance, FY 2022 and 2023
Table 87: Sysmex Corp.: Product Portfolio
Table 88: Sysmex Corp.: News/Key Developments, 2021-2023
Table 89: Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 90: Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2021 and 2022
Table 91: Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 92: Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023
List of Figures
Summary Figure: Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, 2021-2029
Figure 1: Market Dynamics of Drugs and Diagnostics for Hematological Disorders
Figure 2: Incidence of Blood Cancer Types, by Region, 2022
Figure 3: Clinical Trial Phases of Drugs for Various Blood-Related Disorders, March 2024
Figure 4: Global Market Shares of Drugs and Diagnostics for Hematological Disorders, by Segment, 2023
Figure 5: Global Market Shares of Diagnostics for Hematological Disorders, by Product Type, 2023
Figure 6: Global Market Shares of Diagnostics for Hematological Disorders, by End User, 2023
Figure 7: Global Market Shares of Hematology Drugs, by Drug Type, 2023
Figure 8: North American Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
Figure 9: New Cases of Leukemia, Lymphoma and Myeloma in U.S., 2023
Figure 10: European Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
Figure 11: Asia-Pacific Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
Figure 12: Abbott: Revenue Shares, by Business Unit, F.Y. 2023
Figure 13: Abbott: Revenue Shares, by Country/Region, FY 2023
Figure 14: Amgen Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 15: Amgen Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 16: Bio-Rad Laboratories Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 17: Bio-Rad Laboratories Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 18: Bristol Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023
Figure 19: Bristol Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023
Figure 20: Danaher Corp.: Revenue Shares, by Business Unit, FY 2023
Figure 21: Danaher Corp.: Revenue Shares, by Country/Region, FY 2023
Figure 22: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 23: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
Figure 24: Novartis AG: Revenue Shares, by Business Unit, FY 2023
Figure 25: Novartis AG: Revenue Shares, by Country/Region, FY 2023
Figure 26: Sanofi: Revenue Shares, by Business Unit, FY 2023
Figure 27: Sanofi: Revenue Shares, by Country/Region, FY 2023
Figure 28: Sysmex Corp.: Revenue Shares, by Business Unit, FY 2023
Figure 29: Sysmex Corp.: Revenue Shares, by Country/Region, FY 2023
Figure 30: Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Country/Region, FY 2022
